KD-Validated Bcl10 Recombinant Rabbit Monoclonal Antibody

Description

EnkiLife offers the KD-Validated Bcl10 Recombinant Rabbit Monoclonal Antibody. This antibody reacts with Human and is suitable for WB,FCM,ICC application. The product boasts remarkable high specificity, outstanding reproducibility, and exceptional affinity, making it a reliable and superior choice for your needs. Dilution Ratio: WB 1:1,000-1:5,000; FC 1:200-1:2,000; ICC 1:100-1:1,000 Alternative Names of Immunogen:BCL10; BCL10 Immune Signaling Adaptor; CIPER; C-E10; ME10; CLAP; CARMEN; CED-3/ICH-1 Prodomain Homologous E10-Like Regulator; Mammalian CARD-Containing Adapter Molecule E10; CARD-Containing Molecule Enhancing NF-Kappa-B; Caspase-Recruiting Domain-Containing Protein; CARD-Containing Apoptotic Signaling Protein; CARD Containing Molecule Enhancing NF-KB; CARD-Containing Proapoptotic Protein; CARD-Like Apoptotic Protein; B-Cell Lymphoma/Leukemia 10; Cellular Homolog Of VCARMEN; B Cell CLL/Lymphoma 10; Cellular-E10; CCARMEN; HCLAP; BCL10, Immune Signaling Adaptor; B-Cell; CLL/Lymphoma 10; Bcl-10; IMD37 Background: This gene was identified by its translocation in a case of mucosa-associated lymphoid tissue (MALT) lymphoma. The protein encoded by this gene contains a caspase recruitment domain (CARD), and has been shown to induce apoptosis and to activate NF-kappaB. This protein is reported to interact with other CARD domain containing proteins including CARD9, 10, 11 and 14, which are thought to function as upstream regulators in NF-kappaB signaling. This protein is found to form a complex with MALT1, a protein encoded by another gene known to be translocated in MALT lymphoma. MALT1 and this protein are thought to synergize in the activation of NF-kappaB, and the deregulation of either of them may contribute to the same pathogenetic process that leads to the malignancy. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Mar 2016] Research Area: Cell Biology,Signal Transduction,Cancer,Metabolism